TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34038451

Group type: EXPERIMENTAL
Intervention: Ordinary dog visits (D)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Dog visits with an activity (DA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Visits with activity but no dog (A)
Number of subjects: 174
Study: 32854145

Group type: EXPERIMENTAL
Intervention: Immunotherapy (BILITE design)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional design (control)
Number of subjects: 0
Study: 34059275

Group type: EXPERIMENTAL
Intervention: Test RDA∼58
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Test RDA∼77
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ref RDA∼80
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ref RDA∼120
Number of subjects: 220
Study: 32392576

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 162

Group type: COMPARATOR
Intervention: Held-only controls
Number of subjects: 162
Study: 33234641

Group type: EXPERIMENTAL
Intervention: Community Health Intervention through Musical Engagement (CHIME)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 124
Study: 34591168

Group type: EXPERIMENTAL
Intervention: Lc-Hs (polyphenolic extract from Lippia citriodora and Hibiscus sabdariffa)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pla (placebo)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lc-Hs
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pla
Number of subjects: 33
Study: 33283289

Group type: EXPERIMENTAL
Intervention: Tweeting in response to sexism
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-tweet control condition
Number of subjects: 0
Study: 34839872

Group type: EXPERIMENTAL
Intervention: Early rehabilitation exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (lower limb barometry only)
Number of subjects: 72
Study: 32023923

Group type: EXPERIMENTAL
Intervention: Confident Body, Confident Child (CBCC) resource + workshop
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: nutrition booklet
Number of subjects: 89

Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 89
Study: 34551271

Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Number of subjects: 27
Study: 35420710

Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking during the first month of treatment
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking during the last month of treatment
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking between weekly/bi-weekly sessions
Number of subjects: 1383
Study: 32096313

Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 6 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 9 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GSK2878175 long-acting injectable at 400 mg
Number of subjects: 26
Study: 34428642

Group type: EXPERIMENTAL
Intervention: TranS‐C + UC
Number of subjects: 121

Group type: COMPARATOR
Intervention: UC-DT
Number of subjects: 121
Study: 35467962

Group type: EXPERIMENTAL
Intervention: Breathing and relaxation exercises performed via telerehabilitation, twice daily for 4 weeks, with one session supervised by a physiotherapist.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received an information session about COVID-19 via mobile phone video application.
Number of subjects: 50
Study: 33082244

Group type: EXPERIMENTAL
Intervention: Low-fat, restricted-calorie diet
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Mediterranean, restricted-calorie diet
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, non-restricted-calorie diet
Number of subjects: 235

Group type: COMPARATOR
Intervention: All diets (Low-fat, Mediterranean, Low-carbohydrate)
Number of subjects: 235
Study: 34299702

Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF) limited to an 8-h eating window
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular diet (non-TRF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Number of subjects: 12
Study: 32371536

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection evidence in renal tissue via light and electron microscopy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Light microscopy findings
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Electron microscopy findings
Number of subjects: 1
Study: 33940496

Group type: EXPERIMENTAL
Intervention: Hippotherapy (16 sessions of 30 minutes, twice a week)
Number of subjects: 33
Study: 32634656

Group type: EXPERIMENTAL
Intervention: Modified photodynamic therapy (M-PDT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (C-PDT)
Number of subjects: 24
Study: 36091003

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, intravenous drip, once every 3 weeks) combined with apatinib (250 mg, oral administration, once a day) plus capecitabine (1000 mg/m2, twice a day; after 2 weeks of oral administration, the drug was stopped for 1 week; course of treatment, 3 weeks)
Number of subjects: 47
Study: 35990804

Group type: EXPERIMENTAL
Intervention: Calanus oil supplementation with exercise program (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo with exercise program (n = 27)
Number of subjects: 55
Study: 33835175

Group type: EXPERIMENTAL
Intervention: E‐WORTH (5‐session culturally tailored group‐based intervention including a 1‐hour individual HIV testing and orientation session and 4 weekly 90‐minute group sessions)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: E‐WORTH
Number of subjects: 352

Group type: COMPARATOR
Intervention: Streamlined HIV testing control condition (1‐session of HIV testing and information)
Number of subjects: 352
Study: 32324082

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4859

Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 4859
Study: 33390189

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social activity control
Number of subjects: 0
Study: 33028310

Group type: EXPERIMENTAL
Intervention: Health facility readiness score (median readiness score of 53.8% with IQR: 46.2 to 69.2%)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Knowledge score for midwives in public facilities (median(IQR): 8(5 to 12))
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Knowledge of severe pre-eclampsia diagnosis
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Administration of magnesium sulfate for severe pre-eclampsia
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Administration of anti-hypertensive drugs for severe pre-eclampsia
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Awareness of prophylactic use of aspirin to prevent pre-eclampsia
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Awareness of prophylactic use of calcium to prevent pre-eclampsia
Number of subjects: 197
Study: 36501186

Group type: COMPARATOR
Intervention: OliPhenolia® (OliP) 2 × 28 mL∙d−1 for 16 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: OliPhenolia® (OliP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 29
Study: 33634964

Group type: EXPERIMENTAL
Intervention: Maternal type 1 diabetes (T1D)
Number of subjects: 218227

Group type: EXPERIMENTAL
Intervention: Maternal type 2 diabetes (T2D)
Number of subjects: 218227

Group type: EXPERIMENTAL
Intervention: Medicated gestational diabetes (GDM)
Number of subjects: 218227

Group type: EXPERIMENTAL
Intervention: Unmedicated gestational diabetes (GDM)
Number of subjects: 218227

Group type: COMPARATOR
Intervention: No diabetes during pregnancy
Number of subjects: 218227
Study: 33115894

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT, 9000 lux, 5000 K)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dim red light therapy (DRLT, 100 lux, 2700 K)
Number of subjects: 67
Study: 35170144

Group type: EXPERIMENTAL
Intervention: Nebulised gentamicin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 34414832

Group type: EXPERIMENTAL
Intervention: Positive-word stimuli via a smartphone application (3-min videos displaying positive-word stimuli every 5 seconds)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group using the same application but without positive-word stimuli in the videos
Number of subjects: 62
Study: 34391230

Group type: EXPERIMENTAL
Intervention: Lymphatic drainage therapy (LDT) applied for 45 minutes by an experienced physical therapist.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CT: rest) received 45 minutes supine on the treatment table.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (LDT and control) during straight leg raise (SLR).
Number of subjects: 66

Group type: COMPARATOR
Intervention: LDT and control groups.
Number of subjects: 66
Study: 32903262

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat, 22% monounsaturated fatty acids [MUFAs], and <50% carbohydrates)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Low-fat diet (28% fat, 12% MUFAs, and >55% carbohydrates)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 805
Study: 34283210

Group type: EXPERIMENTAL
Intervention: Mild retinopathy (grades 1 and 2 combined)
Number of subjects: 9793

Group type: EXPERIMENTAL
Intervention: Severe retinopathy (grades 3 and 4 combined)
Number of subjects: 9793
Study: 32239322

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2400 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 34
Study: 35894893

Group type: EXPERIMENTAL
Intervention: Superimposed Russian Current (SRC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Russian Current (RC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Voluntary Isometric Contraction (IC)
Number of subjects: 76
Study: 34425828

Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) administered within 6 to 12 hours after birth
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) in subgroup analysis of neonates with birthweight less than 1500g
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine care (control group) in subgroup analysis of neonates with birthweight less than 1500g
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) and routine care
Number of subjects: 156
Study: 32200361

Group type: EXPERIMENTAL
Intervention: 3D pick-and-place task (10Cubes) using a virtual reality system with a Leap Motion Controller (LMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D equipment
Number of subjects: 0
Study: 34287902

Group type: COMPARATOR
Intervention: CTG+CAF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VCMX+CAF
Number of subjects: 30
Study: 32243885

Group type: EXPERIMENTAL
Intervention: High-Definition tDCS over right dorsolateral prefrontal cortex
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High-Definition tDCS over right posterior parietal cortex (PPC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 92
Study: 35411579

Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TBP‐PI‐HBr reference (clinical trial tablet)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet) under fed conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet) and reference (clinical trial tablet)
Number of subjects: 36
Study: 34082645

Group type: EXPERIMENTAL
Intervention: Educational programme (acceptance and commitment training); n = 16; two group-format educational sessions.
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention; n = 18; control group.
Number of subjects: 34
Study: 32843108

Group type: EXPERIMENTAL
Intervention: Stationary ambulance
Number of subjects: 27

Group type: COMPARATOR
Intervention: In-motion ambulance
Number of subjects: 27
Study: 34459694

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 2029
Study: 34655316

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus 60 mg codeine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 35545724

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Single-agent treatment of physician’s choice (TPC)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) with prior CDK4/6 inhibitors
Number of subjects: 468

Group type: COMPARATOR
Intervention: Single-agent treatment of physician’s choice (TPC) with prior CDK4/6 inhibitors
Number of subjects: 468
Study: 33464670

Group type: EXPERIMENTAL
Intervention: Cannabis use on days of alcohol consumption
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of cannabis use effects
Number of subjects: 96
Study: 33872462

Group type: EXPERIMENTAL
Intervention: Corticosteroid (cocktail A: local anesthetics and corticosteroid)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-carboxymethylcellulose (HA-CMC) (cocktail B: local anesthetics and HA-CMC)
Number of subjects: 44
Study: 35905305

Group type: EXPERIMENTAL
Intervention: Buccally absorbed CBD (25 mg 3 times a day if <80 kg, or 50 mg 3 times a day if >80 kg) for 14 days postoperatively
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 34226219

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) plus best practice treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Best practice treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 200
Study: 32723572

Group type: EXPERIMENTAL
Intervention: Cost cohort (exposed to societal cost information)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Cost cohort (participants without previous CTS diagnosis)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control cohort (no cost information)
Number of subjects: 304
Study: 36063058

Group type: EXPERIMENTAL
Intervention: Conventional open surgical treatment (Group 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Endovenous glue ablation (Group 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (Group 3)
Number of subjects: 112
Study: 32102680

Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium co-supplementation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33054533

Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 244
Study: 32986960

Group type: EXPERIMENTAL
Intervention: COPD-Relative Intensity (COPD-RI) exercise training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: COPD-Absolute Intensity (COPD-AI) exercise training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sedentary Healthy Subjects (SHS) exercise training
Number of subjects: 21

Group type: COMPARATOR
Intervention: COPD serum
Number of subjects: 21

Group type: COMPARATOR
Intervention: SHS serum
Number of subjects: 21
Study: 35599474

Group type: EXPERIMENTAL
Intervention: RT-BFR (low-intensity with blood flow restriction, 30% of 1RM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RT-HI (high-intensity without blood flow restriction, 70% of 1RM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: RT-CON (low-intensity without blood flow restriction, 30% of 1RM)
Number of subjects: 32
Study: 34763338

Group type: COMPARATOR
Intervention: 3% Hypertonic Saline (HS), 5 ml/kg as continuous infusion, titrated every 6 hours to achieve serum sodium <160
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 20% Mannitol (MT), 1 g/kg as IV bolus, repeated every six hours
Number of subjects: 51
Study: 32277519

Group type: EXPERIMENTAL
Intervention: Computerized training of emotion recognition ability (TERA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham training (recognition of different types of clouds)
Number of subjects: 40
Study: 35078404

Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N2D)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N1D)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006 (N2D or N1D)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: 1L polyethylene glycol (PEG) NER1006
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Time between preparation and colonoscopy
Number of subjects: 1307
Study: 32421187

Group type: EXPERIMENTAL
Intervention: BariFit mHealth intervention (16-week pilot)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Variable step goals
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Activity suggestions (SMS-delivered)
Number of subjects: 51
Study: 35555290

Group type: EXPERIMENTAL
Intervention: 30-min WBHS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60-min WBHS
Number of subjects: 20
Study: 32844328

Group type: EXPERIMENTAL
Intervention: Dating Matters (DM)
Number of subjects: 1662

Group type: COMPARATOR
Intervention: Standard-of-Care (SC)
Number of subjects: 1662
Study: 33998168

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML) treatment
Number of subjects: 39
Study: 33752634

Group type: EXPERIMENTAL
Intervention: Hazardous alcohol use (AUDIT ≥8)
Number of subjects: 166
Study: 32141320

Group type: EXPERIMENTAL
Intervention: Early weightbearing at 2 weeks postoperation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Late weightbearing at 6 weeks postoperation
Number of subjects: 50
Study: 36377063

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program for 14 ± 2 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program
Number of subjects: 90
Study: 32210537

Group type: EXPERIMENTAL
Intervention: DEX group (loading dose of DEX at 0.5 μg/kg within 10 min, followed by infusion of DEX at 0.5 μg/kg/h until the end of surgery and PCIA for 2 days with DEX plus sufentanil)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: DEX group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 160
Study: 33323237

Group type: EXPERIMENTAL
Intervention: DBLG1 hybrid closed-loop system
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sensor-assisted pump therapy
Number of subjects: 68
Study: 35939964

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control topics within a broader digital competition
Number of subjects: 499
Study: 33323253

Group type: EXPERIMENTAL
Intervention: Innovative intelligent insole system with audiovisual alerts via smartwatch
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Good compliers in intervention group (n=40)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Re-ulcerating patients
Number of subjects: 90
Study: 35702841

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Remogliflozin
Number of subjects: 480
Study: 33653300

Group type: EXPERIMENTAL
Intervention: Usual care plus medication self-management intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 35258131

Group type: EXPERIMENTAL
Intervention: Autogenous tooth roots (TRs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cortical autogenous bone blocks (ABs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (TR and AB)
Number of subjects: 28
Study: 32061431

Group type: EXPERIMENTAL
Intervention: Maxillomandibular fixation (MMF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rigid internal fixation (ORIF)
Number of subjects: 40
Study: 33119861

Group type: EXPERIMENTAL
Intervention: SDZ-ADL 40 mg subcutaneous every other week from Week 0 to Week 24, continued for patients with moderate response at Week 24 (n = 159)
Number of subjects: 353

Group type: COMPARATOR
Intervention: ref-ADL (n = 176) switched to SDZ-ADL at Week 24 (n = 166)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: SDZ-ADL after switching from ref-ADL
Number of subjects: 353

Group type: COMPARATOR
Intervention: ref-ADL switched to SDZ-ADL
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: SDZ-ADL
Number of subjects: 353
Study: 36286853

Group type: EXPERIMENTAL
Intervention: LPD with soy protein (60% soy protein + 40% vegetable proteins) + KA
Number of subjects: 85

Group type: COMPARATOR
Intervention: LPD (60% animal protein + 40% vegetable protein) + KA
Number of subjects: 85
Study: 33523513

Group type: EXPERIMENTAL
Intervention: tildrakizumab 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tildrakizumab 200 mg
Number of subjects: 120
Study: 35691324

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses, administered 28 days or 84 days apart.
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (capsular group B meningococcal vaccine).
Number of subjects: 262